These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34297829)

  • 1. Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab.
    Puzzolo MC; Radice G; Peragine N; de Propris MS; Mariglia P; Vignetti M; Vitale A; Bassan R; Annunziata M; Gaidano G; Rambaldi A; Chiaretti S; Guarini A; Foà R
    Blood; 2021 Dec; 138(22):2290-2293. PubMed ID: 34297829
    [No Abstract]   [Full Text] [Related]  

  • 2. The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or Philadelphia chromosome-like acute lymphoblastic leukemia.
    Wu X; Lu S; Zhang X; Yang Z; Sun A; Wu D; Zhou H; Miao M
    Cancer Med; 2024 Sep; 13(17):e70161. PubMed ID: 39240182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia.
    Haddad FG; Kourie HR; Saleh K
    Br J Haematol; 2023 Sep; 202(6):1084-1086. PubMed ID: 37525325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
    King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
    Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
    Foà R; Bassan R; Vitale A; Elia L; Piciocchi A; Puzzolo MC; Canichella M; Viero P; Ferrara F; Lunghi M; Fabbiano F; Bonifacio M; Fracchiolla N; Di Bartolomeo P; Mancino A; De Propris MS; Vignetti M; Guarini A; Rambaldi A; Chiaretti S;
    N Engl J Med; 2020 Oct; 383(17):1613-1623. PubMed ID: 33085860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
    Rambaldi A; Ribera JM; Kantarjian HM; Dombret H; Ottmann OG; Stein AS; Tuglus CA; Zhao X; Kim C; Martinelli G
    Cancer; 2020 Jan; 126(2):304-310. PubMed ID: 31626339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.
    Samra B; Jabbour E; Ravandi F; Kantarjian H; Short NJ
    J Hematol Oncol; 2020 Jun; 13(1):70. PubMed ID: 32503572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific antibodies in acute lymphoblastic leukemia therapy.
    Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
    Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports.
    Yuda J; Yamauchi N; Kuzume A; Guo YM; Sato N; Minami Y
    J Med Case Rep; 2021 Mar; 15(1):164. PubMed ID: 33762010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax and blinatumomab based chemotherapy-free treatment in a patient with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Chang J; Shen YJ; Shi T; Wang HF; Jin J; Zhu HH
    Ann Hematol; 2023 May; 102(5):1275-1277. PubMed ID: 36892592
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
    Ottmann OG; Pfeifer H
    Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody based therapy in relapsed acute lymphoblastic leukemia.
    Jammal N; Chew S; Jabbour E; Kantarjian H
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101225. PubMed ID: 33279181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
    Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A closer look at blinatumomab.
    Mattison RJ
    Clin Adv Hematol Oncol; 2018 Jun; 16(6):412-414. PubMed ID: 30067611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment.
    Mustafa Ali MK; Sabha MM; Al-Rabi KH
    Platelets; 2015; 26(5):491-4. PubMed ID: 25025538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study.
    Jabbour E; Patel K; Jain N; Duose D; Luthra R; Short NJ; Zugmaier G; San Lucas A; Velasco K; Tran Q; Zaman F; Konopleva M; Kantarjian H
    Am J Hematol; 2021 Oct; 96(10):E379-E383. PubMed ID: 34161631
    [No Abstract]   [Full Text] [Related]  

  • 17. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib.
    Morishita T; Hayakawa F; Sugimoto K; Iwase M; Yamamoto H; Hirano D; Kojima Y; Imoto N; Naoe T; Kiyoi H
    Oncotarget; 2016 Aug; 7(35):56241-56252. PubMed ID: 27494842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic trichosporonosis mimicking disseminated varicella zoster viral infection during blinatumomab therapy.
    Chan TSY; Kwong YL
    Ann Hematol; 2018 Feb; 97(2):371-373. PubMed ID: 29032509
    [No Abstract]   [Full Text] [Related]  

  • 19. A balancing act: Blinatumomab use in a rare occurrence of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia in an adolescent patient with Down syndrome.
    Rav ES; Wahba A; Patnaik A; Toruner G; Hittle A; Toepfer L; Roth M; Cuglievan B; Nunez C; McCall D
    Pediatr Blood Cancer; 2023 May; 70(5):e30191. PubMed ID: 36602024
    [No Abstract]   [Full Text] [Related]  

  • 20. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.
    Rousselot P; Coudé MM; Gokbuget N; Gambacorti Passerini C; Hayette S; Cayuela JM; Huguet F; Leguay T; Chevallier P; Salanoubat C; Bonmati C; Alexis M; Hunault M; Glaisner S; Agape P; Berthou C; Jourdan E; Fernandes J; Sutton L; Banos A; Reman O; Lioure B; Thomas X; Ifrah N; Lafage-Pochitaloff M; Bornand A; Morisset L; Robin V; Pfeifer H; Delannoy A; Ribera J; Bassan R; Delord M; Hoelzer D; Dombret H; Ottmann OG;
    Blood; 2016 Aug; 128(6):774-82. PubMed ID: 27121472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.